The Race to Find the Tangier Disease Gene

For this article, Brendan A. Maher interviewed Michael R. Hayden, director and senior scientist, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Canada; Stephan Rust, cholesterol metabolism group leader at the Institut für Arterioskleroseforschung an der Westfälischen Wilhelms-Universistät; and Gerd Schmitz, a physician and director of the Institut for Clinical Chemistry and Laboratory Medicine, University Hospital, Regensburg. Data from the Web of

Written byBrendan Maher
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

One of Tangier's most striking characteristics is the dramatic deficiency of high-density lipoprotein (HDL)--the so-called good cholesterol that is believed to transport excessive cholesterol from the bloodstream and transfer it to the liver where it can be expelled. The disease--also characterized by enlarged liver and spleen, peripheral neuropathy, lipid deposits in various body parts, and premature coronary artery disease--was seen as a perfect dysfunctional model for the elusive molecular basis of reverse cholesterol transport. Further, the connection with coronary artery disease (CAD), and correlation between low HDL levels and risk for CAD meant to researchers that a better understanding of Tangier could aid in fighting heart disease, a leading killer in the civilized world.

In the late 1990s, as new methods and advanced technologies in genetics became available, researchers broke into the final stretch. A linkage study mapped the gene to 9q31 in 19982 and in June of that year, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies